PMVP — PMV Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-09-25.
Performance
Technicals
Others in Healthcare
Measured signals that fired on PMVP
| date | signal | measured base rate |
|---|---|---|
| 2026-04-06 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-10-27 | Mack David Henry President and CEO | Option exercise | 220.6K | 1.37 | 302.3K |
| 2025-10-23 | ORBIMED ADVISORS LLC | Open-market sale | 1.0M | 1.52 | 1.5M |
| 2025-10-23 | OrbiMed Capital GP V LLC | Open-market sale | 1.0M | 1.52 | 1.5M |
| 2025-09-10 | ORBIMED ADVISORS LLC | Open-market sale | 500.0K | 1.80 | 900.0K |
| 2025-09-10 | OrbiMed Capital GP V LLC | Open-market sale | 500.0K | 1.80 | 900.0K |
| 2025-07-01 | Mack David Henry President and CEO | Open-market sale | 58.4K | 1.06 | 61.9K |
| 2025-07-01 | Jalota Deepika Chief Development Officer | Open-market sale | 33.1K | 1.06 | 35.0K |
| 2025-07-01 | Carulli Michael Chief Financial Officer | Open-market sale | 28.2K | 1.06 | 29.9K |
| 2025-07-01 | Ticktin Robert General Counsel & COO | Open-market sale | 23.2K | 1.06 | 24.5K |
| 2025-01-03 | Mack David Henry President and CEO | Option exercise | 17.7K | 0.53 | 9.4K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BML Capital Management, LLC | 6.6M | 5.3M |
| TANG CAPITAL MANAGEMENT LLC | 5.3M | 4.2M |
| Sio Capital Management, LLC | 3.8M | 3.1M |
| ArrowMark Colorado Holdings LLC | 3.6M | 2.9M |
| Euclidean Capital LLC | 3.3M | 2.6M |
| Eversept Partners, LP | 2.9M | 2.3M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.4M | 2.0M |
| TWO SIGMA INVESTMENTS, LP | 2.3M | 1.9M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.3M | 1.9M |
| BlackRock, Inc. | 1.1M | 874.4K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-07-28 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-07-10 | — | on EDGAR ↗ |
| 4 | 2026-06-05 | 2026-06-04 | on EDGAR ↗ |
| 4 | 2026-06-05 | 2026-06-04 | on EDGAR ↗ |
| 4 | 2026-06-05 | 2026-06-04 | on EDGAR ↗ |
| 4 | 2026-06-05 | 2026-06-04 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- PMV Pharmaceuticals GAAP EPS of -$0.34 beats by $0.05 · 2026-08-14
- PMV Pharmaceuticals, Inc. (PMVP) filed form 8-K · 2026-08-14 · SEC EDGAR
- PMV Pharmaceuticals, Inc. (PMVP) filed form 10-Q · 2026-08-14 · SEC EDGAR
- PMV Pharmaceuticals, Inc. (PMVP) filed form 8-K · 2026-08-14 · SEC EDGAR
Ask the AI about PMVP
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →